Eskatrol

Eskatrol is a brand name for the combination of Phenylpropanolamine and Dexfenfluramine, two drugs that were previously used in the treatment of obesity.

Composition

Eskatrol is composed of two main active ingredients: Phenylpropanolamine and Dexfenfluramine.

Phenylpropanolamine

Phenylpropanolamine (PPA) is a sympathomimetic agent which is used as a decongestant and appetite suppressant. It was withdrawn from the market in many countries due to an increased risk of hemorrhagic stroke.

Dexfenfluramine

Dexfenfluramine is a serotonergic anorectic drug, which was used to treat obesity. It was withdrawn from the market in 1997 due to concerns about heart valve disease.

Uses

Eskatrol was primarily used as an appetite suppressant in the treatment of obesity. It was intended to be used in conjunction with a comprehensive weight management program that included dietary changes and exercise.

Side Effects

The use of Eskatrol could lead to a number of side effects, including increased heart rate, high blood pressure, dry mouth, insomnia, and constipation. More serious side effects included pulmonary hypertension and heart valve disease.

Withdrawal from Market

Eskatrol was withdrawn from the market due to concerns about the safety of its active ingredients. Phenylpropanolamine was associated with an increased risk of hemorrhagic stroke, while Dexfenfluramine was linked to heart valve disease.

See Also

• Anorectic
• Obesity
• Phenylpropanolamine
• Dexfenfluramine

This article is a stub related to pharmacology. You can help WikiMD by expanding it!